Condition category
Infections and Infestations
Date applied
Date assigned
Last edited
Prospectively registered
Overall trial status
Recruitment status
No longer recruiting
Publication status

Plain English Summary

Not provided at time of registration

Trial website

Contact information



Primary contact

Dr Marilla Lucero


Contact details

Research Institute for Tropical Medicine
Filinvest Corporate City
Muntinlupa City

Additional identifiers

EudraCT number number

Protocol/serial number


Study information

Scientific title


Study hypothesis

This study proposes evaluation of immunogenicity and safety of 1 to 3 doses of PCV or alternatively one or two doses of PCV. The vaccines are given within the schedule of the Expanded Programme on Immunisation (EPI) of 6, 10, and 14 weeks common in many developing countries. The proposed age for the first immunisation with PCV is 6 weeks of age, which has the highest coverage and best timeliness in most national programmes. Both PCV and PPS vaccines have been used as a booster following the primary series with PCV. The PPS vaccine with higher PS content (25 mcg vs. 2-10 mcg ) may induce higher GMCs than PCV vaccines, but the avidity of antibodies might be higher following a booster dose of PCV. The results of this study together with information on disease burden estimates and cost-effectiveness analyses could play an important part in the decision-making process or whether or not to include the PCV in the national immunization program.

The primary objective of this study is to compare immune responses following the primary series of one or two doses of PCV to the reference group receiving three doses of PCV when measured at 18 weeks of age.

The secondary objectives are:
1. To describe the peak antibody responses one month after 1, 2 or 3 doses of PCV in early infancy
2. To compare the development of immunological memory by the 3 different immunisation schedules with PCV
3. To assess the immune response to serotypes 1 and 5 present in the PPS but not in the PCV in infants receiving PPS at 9 months of age
4. To describe persistence of serotype specific anti-pneumococcal PS antibodies following three different primary series schedules when measured at 9 months of age
5. To confirm the functional activity of the elicited antibodies by evaluating the opsonophagocytic activity of the antibodies in a randomly selected sub-set of 30 serum samples taken at 18 weeks and 7 days after the vaccinations at 9 months in each of the four study arms
6. To describe safety and tolerability of PCV administered according to the different immunisation schedules (combined active and passive surveillance)
7. To describe the immunogenicity of concomitant vaccine antigens (DT, HBV, Hib) at 18 weeks of age in order to rule out interference caused by PCV

Ethics approval

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design


Secondary study design

Randomised controlled trial

Trial setting

Not specified

Trial type


Patient information sheet




The study is a multi-centre, individual-randomised, open, proof of principle phase II trial to be carried out in Cabuyao, the Philippines with 4 arms. The study groups will receive 1, 2 or 3 doses of 7-valent pneumococcal conjugate vaccine (PCV), reference group will receive the standard 3-dose schedule of PCV and the control group no pneumococcal vaccines except at the exit from study. The effect of boosting at 9 months of age with pneumococcal polysaccharide vaccine after one or two doses of PCV on the antibody concentrations and B cell memory will be studied as well as the possible induction of hyporesponsiveness.

Intervention type



Not Specified

Drug names

Pneumococcal conjugate vaccine

Primary outcome measure

Not provided at time of registration

Secondary outcome measures

Not provided at time of registration

Overall trial start date


Overall trial end date


Reason abandoned (if study stopped)


Participant inclusion criteria

Children who:
1. Are considered to be in good health on the basis of medical history and physical examination
2. Born at full term of pregnancy (≥37 weeks)
3. Are at least 6 weeks (max 9 weeks) of age when starting the Diphtheria, Tetanus, Pertussis (DTP)
4. Whose parents have lived in the study area at least 3 months and have no intention to move out of the area during the next 9 months
5. For whom at least one of the parents or other legally acceptable representative has given his/her informed consent attested by a signature

Participant type


Age group




Target number of participants


Participant exclusion criteria

Children who:
1. Have neurologic disease (an absolute contraindication to the DTP vaccine)
2. Have known or suspected impairment of immunological function
3. Have acute illness at the time of inclusion or have fever (rectal temperature ≥38°C)
4. Have already got their first DTP vaccine dose or first Hepatitis B Virus (HBV) dose, or first Haemophilus influenzae type b (Hib) dose
5. Have known or suspected history of severe atopy
6. Are enrolled or scheduled to be enrolled in another clinical trial
7. Have a history of documented invasive pneumococcal disease
8. Have received a corticosteroid therapy or immunoglobulin or blood products since birth
9. Will be unable to attend the schedule visits and to comply with the study procedures

Recruitment start date


Recruitment end date



Countries of recruitment


Trial participating centre

Research Institute for Tropical Medicine
Muntinlupa City

Sponsor information


Research Institute of Tropical Medicine (Philippines)

Sponsor details

Department of Health Compound
FILINVEST Corporate City
Muntinlupa City

Sponsor type

Research organisation



Funder type

Research organisation

Funder name

World Health Organization (WHO)/Department of Immunisation, Vaccines and Biologicals (IVB) (Switzerland)

Alternative name(s)

Funding Body Type

Funding Body Subtype


Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Participant level data

Not provided at time of registration

Basic results (scientific)

Publication list

2009 results in

Publication citations

  1. Results

    Lucero MG, Nohynek H, Williams G, Tallo V, Simões EA, Lupisan S, Sanvictores D, Forsyth S, Puumalainen T, Ugpo J, Lechago M, de Campo M, Abucejo-Ladesma E, Sombrero L, Nissinen A, Soininen A, Ruutu P, Riley I, Mäkelä HP, Efficacy of an 11-valent pneumococcal conjugate vaccine against radiologically confirmed pneumonia among children less than 2 years of age in the Philippines: a randomized, double-blind, placebo-controlled trial., Pediatr. Infect. Dis. J., 2009, 28, 6, 455-462, doi: 10.1097/INF.0b013e31819637af.

Additional files

Editorial Notes